Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in localized esophageal squamous cell carcinoma
CTR20190198Phase 3Completed
- Sponsor
- BeOne Medicines
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeOne Medicines. Started Jun 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20190198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190198.